StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD)

StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report issued on Sunday. The brokerage issued a hold rating on the stock.

TherapeuticsMD Stock Performance

TherapeuticsMD stock opened at $1.22 on Friday. The business has a 50 day simple moving average of $1.46 and a 200-day simple moving average of $1.67. TherapeuticsMD has a 12 month low of $1.15 and a 12 month high of $2.75.

Institutional Trading of TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP grew its holdings in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the period. Clearline Capital LP owned approximately 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.